Drug intelligence / Profile preview

phthalofyne

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Rectal

Overview

Phthalofyne is a synthetic small molecule drug classified as a benzoic acid ester. It was developed and used primarily as an anthelmintic agent for the treatment of whipworm (Trichuris vulpis) infections in dogs, with the brand name Whipcide. The compound has also been studied for its potential antimicrobial and anticancer activities, including giardiacidal effects and induction of apoptosis in cancer cells, though these uses remain investigational. Its mechanism of action as an anthelmintic is not fully elucidated but is believed to involve disruption of metabolic processes in parasites. Phthalofyne reached up to Phase II clinical trials and was launched for veterinary use in 1954[2][3][5].

Brand names: Whipcide
Other names: 131-67-9

Beyond the preview

Go deeper on phthalofyne.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phthalofyne.

Explore the full profile